The
results point to potential de-worming treatments to help fight
some of the most neglected tropical diseases - including river
blindness, schistosomiasis and hookworm disease - which affect
around a billion people worldwide.
"Parasitic worms are some of our oldest foes and have evolved
over millions of years to be expert manipulators of the human
immune system," said Makedonka Mitreva of Washington
University's McDonnell Genome Institute, who co-led the work
with colleagues from Britain's Wellcome Sanger Institute and
Edinburgh University.
She said the results of this study would lead to both a deeper
knowledge of the biology of parasites and a better understanding
of how human immune systems can be harnessed or controlled.
Parasitic worm infections can last many years and can cause
severe pain, physical disabilities, retarded development in
children and social stigma linked to deformity.
Current medicines to combat them - including drugs made by
Sanofi, GSK and Johnson & Johnson - can be moderately effective
and are often donated by drugmakers or sold at cut-down prices
to those who need them. But the spectrum of drugs to treat worm
infections is still limited.
To try to improve the potential drug pipeline and to understand
how worms invade and take up residence inside humans and other
animals, the research team compared the genomes of 81 species of
roundworms and flatworms, including 45 that had never previously
had their genomes sequenced.
The analysis found almost a million new genes that had not been
seen before, belonging to thousands of new gene families, and
identified many new potential drug targets and drugs.
"We focussed our search by looking at existing drugs for human
illnesses," said the Sanger Institute's Avril Coghlan, who
worked on the team. She said this offered a possible fast-track
route "to pinpointing existing drugs that could be repurposed
for deworming".
The study's findings were published in the journal Nature
Genetics on Monday.
(Editing by Andrew Heavens)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.

|
|